Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

Ronald Carl Petersen, P. S. Aisen, L. A. Beckett, M. C. Donohue, A. C. Gamst, D. J. Harvey, Clifford R Jr. Jack, W. J. Jagust, L. M. Shaw, A. W. Toga, J. Q. Trojanowski, M. W. Weiner

Research output: Contribution to journalArticle

585 Citations (Scopus)

Abstract

BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Aβ-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalNeurology
Volume74
Issue number3
DOIs
StatePublished - Jan 2010

Fingerprint

Neuroimaging
Alzheimer Disease
Biomarkers
Cognitive Dysfunction
Dementia
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., ... Weiner, M. W. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology, 74(3), 201-209. https://doi.org/10.1212/WNL.0b013e3181cb3e25

Alzheimer's Disease Neuroimaging Initiative (ADNI) : Clinical characterization. / Petersen, Ronald Carl; Aisen, P. S.; Beckett, L. A.; Donohue, M. C.; Gamst, A. C.; Harvey, D. J.; Jack, Clifford R Jr.; Jagust, W. J.; Shaw, L. M.; Toga, A. W.; Trojanowski, J. Q.; Weiner, M. W.

In: Neurology, Vol. 74, No. 3, 01.2010, p. 201-209.

Research output: Contribution to journalArticle

Petersen, RC, Aisen, PS, Beckett, LA, Donohue, MC, Gamst, AC, Harvey, DJ, Jack, CRJ, Jagust, WJ, Shaw, LM, Toga, AW, Trojanowski, JQ & Weiner, MW 2010, 'Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization', Neurology, vol. 74, no. 3, pp. 201-209. https://doi.org/10.1212/WNL.0b013e3181cb3e25
Petersen, Ronald Carl ; Aisen, P. S. ; Beckett, L. A. ; Donohue, M. C. ; Gamst, A. C. ; Harvey, D. J. ; Jack, Clifford R Jr. ; Jagust, W. J. ; Shaw, L. M. ; Toga, A. W. ; Trojanowski, J. Q. ; Weiner, M. W. / Alzheimer's Disease Neuroimaging Initiative (ADNI) : Clinical characterization. In: Neurology. 2010 ; Vol. 74, No. 3. pp. 201-209.
@article{a8f4b53488f74923a5448f6c7ae01910,
title = "Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization",
abstract = "BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5{\%} per year. Approximately 50{\%} of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Aβ-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.",
author = "Petersen, {Ronald Carl} and Aisen, {P. S.} and Beckett, {L. A.} and Donohue, {M. C.} and Gamst, {A. C.} and Harvey, {D. J.} and Jack, {Clifford R Jr.} and Jagust, {W. J.} and Shaw, {L. M.} and Toga, {A. W.} and Trojanowski, {J. Q.} and Weiner, {M. W.}",
year = "2010",
month = "1",
doi = "10.1212/WNL.0b013e3181cb3e25",
language = "English (US)",
volume = "74",
pages = "201--209",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Alzheimer's Disease Neuroimaging Initiative (ADNI)

T2 - Clinical characterization

AU - Petersen, Ronald Carl

AU - Aisen, P. S.

AU - Beckett, L. A.

AU - Donohue, M. C.

AU - Gamst, A. C.

AU - Harvey, D. J.

AU - Jack, Clifford R Jr.

AU - Jagust, W. J.

AU - Shaw, L. M.

AU - Toga, A. W.

AU - Trojanowski, J. Q.

AU - Weiner, M. W.

PY - 2010/1

Y1 - 2010/1

N2 - BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Aβ-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.

AB - BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Aβ-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.

UR - http://www.scopus.com/inward/record.url?scp=74949097405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949097405&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181cb3e25

DO - 10.1212/WNL.0b013e3181cb3e25

M3 - Article

C2 - 20042704

AN - SCOPUS:74949097405

VL - 74

SP - 201

EP - 209

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -